三种口服伊特拉科纳配方在表面皮肤植物病中的比较有效性
Harsh Tyagi1, Shitij Goel1, Aneesha Puri1
1Department of Dermatology, Venereology and Leprology, School of Medical Sciences and Research, Sharda Hospital, Greater Noida, Uttar Pradesh, India.
Mycoses
|June 19, 2025
概括
超生物可用的伊特拉科纳 (SUBA-ITZ) 剂量为50mg,与传统的ITZ或3个月后更高的SUBA-ITZ剂量相比,表面皮肤植物病的复发率较低. 需要进一步的长期研究来优化剂量策略.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
背景情况:
- 皮肤植物病是印度普遍存在的公共卫生问题,经常需要系统性抗真菌治疗.
- 传统的伊特拉科纳 (ITZ) 配方表现出可变的口服吸收,影响治疗疗效.
- 超生物可用的伊特拉科纳 (SUBA-ITZ) 具有增强的药理动力学特性,但直接的临床比较有限.
研究的目的:
- 评估和比较三个口服伊特拉可纳配方的疗效,安全性,复发和复发率.
- 研究传统的ITZ 100mg (C-ITZ),SUBA-ITZ 65mg和SUBA-ITZ 50mg,用于治疗表面皮肤植物病.
主要方法:
- 这是一项开放的随机化研究,涉及150名被证实患有表面性皮肤植物病的患者.
- 患者被分配给接受C-ITZ 100mg两次,SUBA-ITZ 65mg两次或SUBA-ITZ 50mg两次,持续6周.
- 临床评估发生在3周和6周,复发和复发被电话监测长达6个月.
主要成果:
- 所有ITZ配方在6周内都表现出可比的短期临床疗效,身体表面积 (BSA),医生的整体评估 (PGA) 和负的KOH显微镜显现出相似的改善.
- 在3个月的随访中,SUBA-ITZ 50mg组的复发和复发率 (10.2%) 与SUBA-ITZ 65mg (31.1%,28.9%) 和C-ITZ 100mg (23.9%,26.1%) 组相比显著降低 (p <0.05).
- 然而,在6个月后的随访中,这些复发和复发率的差异在统计学上并不显著.
结论:
- 所有三种研究的伊特拉可纳配方都显示出对表面皮肤植物病的短期有效性相似.
- 这些发现表明,较低剂量的SUBA-ITZ在减少早期复发和复发方面具有潜在的益处.
- 较大的,长期的随机对照试验对于确定皮肤植物病的最佳伊特拉科纳剂量策略至关重要.
相关概念视频
01:23Skin Diseases and Disorders
4.3K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
4.3K
01:28Antimicrobial Effectiveness
175
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
175
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
210
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
210